not a likely scenario given the fact that ITW is committed to share repurchases as a fundamental part of their shareholder enhancement strategy.
price decline after the earnings announcement seems like a dumb over-reaction to a very good quarter.
C'mon Merck, let's get this right. And no, I don't think approval was priced in. We should go after ESRX approval with a compelling program.
Well done, again!
wrong again, genius.